“Excellent scientific advice provided for the study design. Studies tailored for small biotechs with limited budget. Timelines met, rigor in execution. Indeed, a great partner for drug development in the metabolic disease area.”
Recent News
- Physiogenex to present its obese NASH hamster model at the NAFLD/NASH Keystone Symposia, Banff, AB, Canada March 19-23, 2023 03/15/2023
- Physiogenex to present the SDT fatty rat model at the 5th CKD Summit in Boston, MA, March 7-9, 2023 03/06/2023
- Physiogenex to present its obese NASH hamster model at the Global NASH Congress, London, UK, March 2nd-3rd, 2023 02/27/2023
- Physiogenex to present its obese NASH hamster model at the 2nd HFpEF Summit in Boston, MA, Jan. 25-26, 2023 01/18/2023
- Physiogenex is now ISO 9001:2015 certified! 12/27/2022
- Physiogenex to present its obese NASH hamster model at the 20th World Congress of Insulin Resistance in Los Angeles, CA, Dec 1-3, 2022 11/29/2022